1b:I[76749,["/_next/static/chunks/bf18fea59be6d5b1.js","/_next/static/chunks/1ba21a8e081e29d1.js","/_next/static/chunks/0383663887945ae7.js","/_next/static/chunks/2060b26370dc6c0a.js","/_next/static/chunks/c89b4435b8c37fcf.js","/_next/static/chunks/8ddf2550f38c2f2a.js","/_next/static/chunks/5bf36002c846d2d8.js"],"default"] 1c:I[3486,["/_next/static/chunks/bf18fea59be6d5b1.js","/_next/static/chunks/1ba21a8e081e29d1.js","/_next/static/chunks/0383663887945ae7.js","/_next/static/chunks/2060b26370dc6c0a.js","/_next/static/chunks/c89b4435b8c37fcf.js","/_next/static/chunks/8ddf2550f38c2f2a.js","/_next/static/chunks/5bf36002c846d2d8.js"],"default"] 1d:I[17707,["/_next/static/chunks/bf18fea59be6d5b1.js","/_next/static/chunks/1ba21a8e081e29d1.js","/_next/static/chunks/0383663887945ae7.js","/_next/static/chunks/2060b26370dc6c0a.js","/_next/static/chunks/c89b4435b8c37fcf.js","/_next/static/chunks/8ddf2550f38c2f2a.js","/_next/static/chunks/5bf36002c846d2d8.js"],"default"] 1e:I[66528,["/_next/static/chunks/bf18fea59be6d5b1.js","/_next/static/chunks/1ba21a8e081e29d1.js","/_next/static/chunks/0383663887945ae7.js","/_next/static/chunks/2060b26370dc6c0a.js","/_next/static/chunks/c89b4435b8c37fcf.js","/_next/static/chunks/8ddf2550f38c2f2a.js","/_next/static/chunks/5bf36002c846d2d8.js"],"default"] 1f:I[63176,["/_next/static/chunks/bf18fea59be6d5b1.js","/_next/static/chunks/1ba21a8e081e29d1.js","/_next/static/chunks/0383663887945ae7.js","/_next/static/chunks/2060b26370dc6c0a.js","/_next/static/chunks/c89b4435b8c37fcf.js","/_next/static/chunks/8ddf2550f38c2f2a.js","/_next/static/chunks/5bf36002c846d2d8.js"],"default"] 20:I[87099,["/_next/static/chunks/bf18fea59be6d5b1.js","/_next/static/chunks/1ba21a8e081e29d1.js","/_next/static/chunks/0383663887945ae7.js","/_next/static/chunks/2060b26370dc6c0a.js","/_next/static/chunks/c89b4435b8c37fcf.js","/_next/static/chunks/8ddf2550f38c2f2a.js","/_next/static/chunks/5bf36002c846d2d8.js"],"default"] 21:I[26200,["/_next/static/chunks/bf18fea59be6d5b1.js","/_next/static/chunks/1ba21a8e081e29d1.js","/_next/static/chunks/0383663887945ae7.js","/_next/static/chunks/2060b26370dc6c0a.js","/_next/static/chunks/c89b4435b8c37fcf.js","/_next/static/chunks/8ddf2550f38c2f2a.js","/_next/static/chunks/5bf36002c846d2d8.js"],"Group"] 22:I[23365,["/_next/static/chunks/bf18fea59be6d5b1.js","/_next/static/chunks/1ba21a8e081e29d1.js","/_next/static/chunks/0383663887945ae7.js","/_next/static/chunks/2060b26370dc6c0a.js","/_next/static/chunks/c89b4435b8c37fcf.js","/_next/static/chunks/8ddf2550f38c2f2a.js","/_next/static/chunks/5bf36002c846d2d8.js"],"default"] 23:T52d,¹⁷⁷Lu-PSMA-617 and ¹⁷⁷Lu-PSMA I&T (collectively termed ¹⁷⁷Lu-PSMA) are currently being used for the treatment of selected metastatic castration-resistant prostate cancer (mCRPC) patients with PSMA PET-positive disease, but biomarkers for these agents remain incompletely understood. Methods: Pretreatment circulating tumor DNA (ctDNA) samples were collected from 44 mCRPC patients receiving ¹⁷⁷Lu-PSMA treatment. Prostate-specific antigen responders and nonresponders were assessed relative to the ctDNA findings at baseline. Results: The ctDNA findings indicated that nonresponders were more likely to have gene amplifications than were responders (75% vs. 39.2%, P = 0.03). In particular, amplifications in FGFR1 (25% vs. 0%, P = 0.01) and CCNE1 (31.2% vs. 0%, P = 0.001) were more likely to be present in nonresponders. CDK12 mutations were more likely to be present in nonresponders (25% vs. 3.6%, P = 0.05). Conclusion: Our analyses indicate that ctDNA assays may contain specific biomarkers predictive of response or resistance for ¹⁷⁷Lu-PSMA-treated mCRPC patients. Additional confirmatory studies are required before clinicians can use these findings to make personalized treatment decisions.

Minqui Huang

Publications